



**HEART FAILURE
ASSOCIATION OF INDIA**
Improving Heart Failure Care

**9th Annual conference of Heart Failure Association of India
In association with Heart Failure Association of the ESC**



HFAI 2023

10th - 12th, February 2023

**Taj Wellington Mews, Chennai
& Online**

**SCIENTIFIC
PROGRAMME**

In Collaboration with

**Heart Failure Society of America
Society of Advanced Heart & Lung Disease
Society of Heart Failure & Transplantation
Indian Society of Heart & Lung Transplant**

Academic Partner



www.hfai.co.in

Scientific Program (Physical)

*Cardiology Programme at Taj Wellington Mews, Chennai
Relayed Live Online

DAY
01

Friday - 10th February 2023

10.30-11.30 AM

Session 1

CKD in Diabetes-Prevalence, Pathophysiology Impact on Cardiometabolic Diseases

Potassium binding as RAASI enabling therapy- current insights

Cardiorenal syndrome and worsening renal function in AHF on diuretics. Are they the same?

Optimal Assessment of Incident / Underlying renal Dysfunction in Cardiogenic shock.

ARNI vs ARB in cardioreno protective agent

11.30- 12.30 PM

Session 2

Why & When to screen for heart failure and kidney disease in Diabetes

Renal responses to novel chronic heart failure therapies

Renal failure in cardiovascular disease- renal markers what do they tell us

Amplification Of CV Risk in Diabetics With CKD

12.30- 1.30 PM

Session 3

Cardiorenal Interactions Revisited: How to Improve Heart Failure Outcomes in Patients With Chronic Kidney Disease .

Shifting the Treatment Paradigm for Chronic Kidney Disease in Type 2 Diabetes: The Role of Nonsteroidal MRAs

Sodium Restriction in HFrEF – Will Urinary Sodium become a surrogate outcome in AHF trials

1.30- 2.30 PM

Session 4

Why and when to screen for heart failure and kidney disease in diabetes

SGLT2i as Cardioreno protective agent

How to improve heart failure outcomes in patients with CKD

2.30- 3.30 PM

Session 5 DM AND HF

Identifying high risk patients – physicians' perspective

Diabetes and heart failure

Glucocentric Drugs in Cardiovascular Disease Protection and Heart Failure

Biomarkers for the prediction of heart failure and cardiovascular events in patients with type 2 diabetes

3.30-4.45 PM

Session 6
PHARMACOLOGY Reboot

When will I use SGLT2 inhibitors in my practice

Internal medicine perspective

Diabetologists perspective

Nephrologist's perspective

Cardiologist's perspective

When Will I Not Use/ Discontinue SGLT2 Inhibitors In My Practice

Internal Medicine Perspective

Diabetologists perspective

Nephrologist's perspective

Cardiologist's perspective

4.45- 6.00 PM

Session 7
WOMAN AND HF Let's Talk About Sex
(Differences in Heart Failure)

Are women with HF treated equally well

HFpEF - A disease more common in women, but why?

LVAD Therapy and Heart Transplantation in Women - Same Playing Field?

Cardiomyopathies in women: Takotsubo syndrome, peripartum cardiomyopathy, and cardiogenic shock

Sex-related Aspects in DEVICE THERAPY

HF In Women. Data From Chennai

6.00-7.00 PM

Session 8

Pearls for the cardiac intensivist

Diagnosis and treatment of hypertensive pulmonary edema

Cardiogenic shock: keep the organs running!

Liver injury: from transaminitis to secondary sclerosing cholangitis

7.00-8.00 PM

Session 9

Restrictive Cardiomyopathies. Check List For Diagnosis

LV Noncompaction

Obesity related HEFpEF – The next STEP with semaglutide

Cardio-oncology . Current perspectives

Upgrading the role of bedside cardiac-lung ultrasound

Admission and discharge criteria from the Emergency Department



Saturday - 11th February 2023

9.00 -10.00 AM	Session1
CKD in Diabetes – prevalence, pathophysiology and impact in Cardio-metabolic disease	
Kidney failure and renal replacement therapy in patients with acute heart failure and cardiogenic shock	
Renal Failure in Cardio-vascular disease – What do renal markers tell us	
Potassium binding as RAASi enabling therapy – Current insights	
10.00 -11.00 AM	Session 2 - EP/PACING
Conduction pacing or CRT as first line therapy, what is the evidence	
Sudden Cardiac Death in heart failure	
Rhythm control in patients with AF and HF- current concepts and future perspectives.	
Should CMR be mandatory before each ICD implant in patients with heart failure?	
Cardiac Contractility Modulation.	
11.00 -12.00 PM	Session 3
Horizontal or vertical approach in starting fantastic four	
Low dose is better than no dose. But strive for guideline directed doses	
Will ace inhibitors be abandoned in the treatment of HFrEF?	

12.00 -1.00 PM	Session 4
PA pressure monitoring after CHAMPION and GUIDE-HF	
Inter atrial shunts for treatment of heart failure	
Metabolic Modulation In HF	
ReDS system for assessment of lung fluid in heart failure	
Heart Rate Control In HF	
Influenza Vaccinations. Are we underusing it?	
1.00 -2.00 PM	Session 5
Current and emerging approaches in HFpEF diagnosis	
How to practically personalise HFpEF management with established and novel drugs	
The dangerous liaison between epicardial adipose tissue and heart failure	
Pulmonary hypertension in Heart failure (HFpEF and HFREF) . How to manage?	
2.00 -2.45 PM	Session 6 - BIOMARKERS
Natriuretic peptides in Heart Failure: The current paradigm and the future	
Troponins in HF	
Newer biomarkers in HF	
2.45 -3.45 PM	Session 7
ECHO Diagnosis In HFPEF	
Assessing MR IN HF	
Stress Imaging In HFPEF	

3.45-4.45 PM

Session 8

CHIP IN HF To Do Or Send For Transplant

TAVR IN HF

MITRACLIP IN HF Challenges

Percutaneous Therapy In Right Heart Failure

Role Of Support Devices In Advanced HF

4.45-5.00 PM - INAUGURATION

5.00-7.00 PM

**Session 9
Joint Sessions Heart Failure Association Of
The European Society Of Cardiology**

Coronary revascularization in patients with left ventricle systolic dysfunction, current challenges and clinical outcomes

Reconsidering the ejection fraction centric view of pharmacologic treatment for heart failure

Prevention of heart failure events with sodium–glucose co-transporter 2 inhibitors across a spectrum of cardio-renal-metabolic risk

Impact of recent CVOT in contemporary guidelines for HF and CKD

Are there pillars of GDMT in HFpEF?

How to treat congestion- Vasodilators, diuretics or mechanical solutions

7.00-8.00 PM

STRONG HF SYMPOSIUM



Sunday - 12th February 2023

DAY
03

8.30-9.30 AM	QUIZ FINALS
9.30-10.30 AM	Session 1 - GDMT
In my patient GDMT is not working, I need help	
What should I remember and forget from ESC heart failure guidelines	
HFrEF vs HFmrEF vs HFpEF: similarities and differences	
Are there pillars of GDMT in HFpEF	
Managing the patient with worsening heart failure with vericiguat.	
10.30-11.00 AM	Session 2
Redefining and unifying management of heart failure across the spectrum. Learnings from EMPEROR Study programmes and recent updates	
Advanced cancer is a cardiovascular illness — an introduction to a new kind of cardio-oncology	
11.00-12.30 PM	Session 3 Combined Session (Heart Failure Society of America)

REGISTER NOW

CLICK HERE >

For more details contact

Physical Conference

Dr Hilda : 98417 00824

Virtual (Online) Conference

9964153557

9880880682

9972735480

***Cardiology Conference Venue:**

Taj Wellington Mews, Chennai

TRIL Infopark Limited, Rajiv Gandhi

Salai, Tharamani, Chennai

Tamil Nadu 600113

***Surgical Program & Nursing Program
Venue:**

Vivanta Chennai, IT Expressway

309, Rajiv Gandhi Salai, Elcot Sez

Sholinganallur, Chennai, Tamil Nadu 600119

www.hfai.co.in